You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)發布替雷利珠單抗臨床數據
阿思達克 11-26 08:22

百濟神州(06160.HK)公布替雷利珠單抗臨床數據。截至數據截點,8例患者仍在接受替雷利珠單抗治療,包括4例G/GEJ腺癌患者和4例ESCC患者。替雷利珠單抗聯合化療用於治療胃/胃食管結合部腺癌患者以及食管鱗狀細胞癌患者的一項2期臨床試驗的初步數據。

公司腫瘤免疫學首席醫學官賁勇表示:替雷利珠單抗與化療的聯合治療在這項針對G/GEJ腺癌和ESCC患者的試驗中展示了持久的緩解,並且總體耐受。胃癌和食管癌位居全球最常見癌種之列,有著高度未滿足的治療需求,特別是在中國需求更加突出。公司很欣慰能夠在這些癌症以及其他亞洲地區高發癌症中繼續開展替雷利珠單抗的後期開發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account